No Detail Found!

Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer and the effect on its adverse reactions

Author(s)
Wenen Zhou Department of Oncology, First Hospital of Qinhuangdao,Qinhuangdao, Hebei,China
Xueying Su Department of Oncology, First Hospital of Qinhuangdao,Qinhuangdao, Hebei,China
Lusheng Sun General Medicine, First Hospital of Qinhuangdao,Qinhuangdao, Hebei,China
Yanjun Liu General Medicine, First Hospital of Qinhuangdao,Qinhuangdao, Hebei,China
Zhenzhen Wang Department of Oncology, First Hospital of Qinhuangdao,Qinhuangdao, Hebei,China
Xiaoyu Wang Department of Oncology, First Hospital of Qinhuangdao,Qinhuangdao, Hebei,China
Yanhong Yang Department of Oncology, First Hospital of Qinhuangdao,Qinhuangdao, Hebei,China
Abstract
To evaluate the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer and the effect on its adverse reactions, 100 patients with advanced colorectal cancer admitted to our hospital from March 2019 to March 2021 were identified as study subjects and were randomly divided into a control group and an experimental group, with 50 cases in each group. The control group was treated with chemotherapy, and the experimental group was given a combination of bevacizumab with chemotherapy. The treatment efficacy, safety, and incidence of adverse reactions in both groups were analyzed and compared. The effectiveness and disease control rate of the experimental group were 50% and 96%, which were significantly higher than those of 26% and 80% in the control group (P<0.05). After treatment, the experimental group exhibited a significantly lower serum vascular endothelial growth factor level and heat shock protein 90a (HSP90a) level compared with that of the control group (P<0.05). Markedly higher apoptosis index of tumor cells was observed in the experimental group than in the control group (P<0.05). The incidence of adverse reactions was 8% in the experimental group, which was significantly lower than that of 28% in the control group (P<0.05). The post-treatment quality of life scores in the experimental group exceeded that in the control group (P<0.05). Bevacizumab combined with chemotherapy for advanced colorectal cancer boosts treatment efficiency, promotes apoptosis of tumor cells, down regulates HSP90a level and enhances patients' quality of life with high safety, which is worthy of clinical promotion and application.
Publication Details
Page(s) 381-386
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: S1, Year: 2022

Request the full text from PASTIC

Keywords
advanced colorectal cancer, Bevacizumab, Safety, Efficacy, Chemotherapy
References
Amano T,Iijima H,Shinzaki S,Tashiro T,Iwatani S,Tani M,Takehara T .2021 .Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma. BMC Cancer, 21(1) : 978.
Aoshima Y,Karayama M,Inui N,Yasui H,Hozumi H,Suzuki Y,Suda T Y .2021 .Erlotinib and bevacizumab in elderly patients >/=75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Invest New Drugs, 39(1) : 210-216.
Chen JC,Ko JC,Taso YC,Cheng HH,Chen TY,Yen TC,Lin YW,-Demethoxygeldanamycin Enhances YW .2021 .Induced Cytotoxicity in Human Lung Cancer Cells. Pharmacology, 106(3-4) : 154-168.
Chen YL,Huang AP,Wang CC,Chen HY,Chen YF,Xiao F,Hsu FM .2021 .Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis. J. Neurooncol., 153(3) : 455-465.
El-Khouly FE,Veldhuijzen van Zanten SEM,Jansen MHA,Bakker DP,Sanchez Aliaga E,Hendrikse NH,Kaspers GJL .2021 .A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. J Neurooncol, 153(2) : 263-271.
Formica ML,Legeay S,Bejaud J,Montich GG,Ullio Gamboa GV,Benoit JP,Palma SD,Eng. C Mater SD .2021 .Biol. Appl., 119 : 111398.
Higashijima J,Tokunaga T,Yoshimoto T,Eto S,Kashihara H,Takasu C,Shimada M C .2021 .A multicenter phase II trial of preoperative chemoradiotherapy with S-1 plus oxaliplatin and bevacizumab for locally advanced rectal cancer. Int. J. Clin. Oncol., 26(5) : 875-882.
Huang C,Gu X,Zeng X,Chen B,Yu W,Chen M .2021 .Cetuximab versus bevacizumab following prior folfoxiri and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: A retrospective study. BMC Cancer, 21(1) : 30.
Huang LT,Cao R,Wang YR,Sun L,Zhang XY,Guo YJ,Ma J .2021 .Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: Evidence from a meta-analysis of randomized control trials. BMC Cancer, 21(1) : 426.
Jorge DM,Tavares Neto J,Poli-Neto OB,Scott IU,Jorge R .2021 .Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: A randomized clinical trial. Int J Retina Vitreous, 7(1) : 35.
Leslie KK,Filiaci VL,Mallen AR,Thiel KW,Devor EJ,Moxley K,Aghajanian C K .2021 .Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG oncology study. Gynecol Oncol, 161(1) : 113-121.
Li J,Yue H,Yu H,Lu X,Xue X .2021 .Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer. BMC Cancer, 21(1) : 67.
Murakami T,Sugiura Y,Okamoto F,Okamoto Y,Kato A,Hoshi S,Oshika T .2021 .Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. Graefes Arch. Clin. Exp, 259(9) : 2849-2855.
Pena-Cabia S,Royuela Vicente A,Ramos Diaz R,Gutierrez Nicolas F,Penalver Vera A,Siso Garcia I,Lopez-Martin A .2021 .Assessment of exposureresponse relationship for bevacizumab in patients with metastatic colorectal cancer. Biomed, 141 : 111827.
Powles T,Atkins MB,Escudier B,Motzer RJ,Rini BI,Fong L,McDermott DF L .2021 .Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion 150: A randomized phase 2 clinical trial. Eur. Urol., 79(5) : 665-673.
Shukla S,Babcock Z,Pizzi L,Brunetti L L .2021 .Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: A meta-analysis of randomized clinical trials. Curr. Med. Res. Opin., 37(5) : 811-817.
Snyder MH,Ampie L,DiDomenico JD,Asthagiri AR .2021 .Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case. J. Clin. Neurosci., 86 : 79-84.
Svaton M,Blazek J,Krakorova G,Pesek M,Buresova M,Topolcan Z,O Z .2021 .Prognostic role for CYFRA 21-1 in patients with advanced-stage NSCLC treated with bevacizumab plus chemotherapy. Anticancer Res., 41(4) : 2053-2058.
Tamiya M,Tamiya A,Suzuki H,Taniguchi Y,Katayama K,Minomo S,Hirashima T .2021 .Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for nonsquamous non-small cell lung cancer with malignant pleural effusion. Invest New. Drugs, 39(4) : 1106-1112.
Wang Y,Lu LC,Guan Y,Ho MC,Lu S,Spahn J,Hsu CH .2021 .Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp. Hematol. Oncol., 10(1) : 45.
Yoshida Y,Yamada T,Kamiyama H,Kosugi C,Ishibashi K,Yoshida H,Group TCS H .2021 .Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int. J. Clin Oncol., 26(1) : 111-117.
0

Citations

0

Downloads

9

Views